165 related articles for article (PubMed ID: 38490088)
1. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract][Full Text] [Related]
2. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract][Full Text] [Related]
3. Personalizing Medicine With Germline and Somatic Sequencing in Advanced Pancreatic Cancer: Current Treatments and Novel Opportunities.
Lee MS; Pant S
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-13. PubMed ID: 33929876
[TBL] [Abstract][Full Text] [Related]
4. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer.
Ghidini M; Lampis A; Mirchev MB; Okuducu AF; Ratti M; Valeri N; Hahne JC
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33383713
[TBL] [Abstract][Full Text] [Related]
5. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
[TBL] [Abstract][Full Text] [Related]
6. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
7. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
8. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
9. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness.
Quintanilha JCF; Storandt MH; Graf RP; Li G; Keller R; Lin DI; Ross JS; Huang RSP; Schrock AB; Oxnard GR; Chakrabarti S; Mahipal A
JCO Precis Oncol; 2023 Jul; 7():e2300092. PubMed ID: 37410975
[TBL] [Abstract][Full Text] [Related]
11. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma.
Chapin WJ; Reiss KA
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
[TBL] [Abstract][Full Text] [Related]
13. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
14. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Botta GP; Kato S; Patel H; Fanta P; Lee S; Okamura R; Kurzrock R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34375311
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
16. High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.
Karamitopoulou E; Andreou A; Wenning AS; Gloor B; Perren A
Eur J Cancer; 2022 Jul; 169():64-73. PubMed ID: 35512587
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic ductal adenocarcinoma in the era of precision medicine.
Zheng-Lin B; O'Reilly EM
Semin Oncol; 2021 Feb; 48(1):19-33. PubMed ID: 33637355
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
19. Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma.
Quaas A; Heydt C; Waldschmidt D; Alakus H; Zander T; Goeser T; Kasper P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Buettner R; Merkelbach-Bruse S
BMC Gastroenterol; 2019 Feb; 19(1):21. PubMed ID: 30717682
[TBL] [Abstract][Full Text] [Related]
20. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Das S; Cardin D
Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]